Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking's obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market. Oral-2735 Could Be A Game Changer JPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, par ...